BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260305T190000
DTEND;TZID=Africa/Nairobi:20260305T203000
DTSTAMP:20260523T014507
CREATED:20260303T081324Z
LAST-MODIFIED:20260303T083141Z
UID:41277-1772737200-1772742600@kesho-kenya.org
SUMMARY:Women in Oncology
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nWomen in Oncology this International Women’s Day! \nJoin us for a powerful CPD Accredited webinar hosted by KESHO — Kenya Society of Haematology & Oncology \nDate: 5th March 2026 \nTime: 7:00 PM – 8:30 PM EAT \nModerator: \n\nDr. Gladwell Kiarie — Medical Oncologist\, The Nairobi Hospital\n\nSpeakers: \n\nProf. Verna Vanderpuye\n\nSenior Consultant Clinical Oncologist & Deputy Director\, National Centre of Radiotherapy\, Oncology and Nuclear Medicine\, Korle-bu Teaching Hospital\, Accra\, Ghana Topic: Legacy and Leadership: Mentorship from Women Advancing Oncology in Africa \n\nDr. Chemtai Mungo\n\nAssistant Professor of Obstetrics and Gynaecology & Physician-Scientist\, University of North Carolina at Chapel Hill Topic: Purpose-Driven Careers: Global Health\, Research and Women’s Impact in Oncology \n\nDr. Anne Mwirigi\n\nConsultant Haematologist and Assistant Professor\, Aga Khan University Hospital Topic: Growing in Specialised Oncology: Lessons in Haematology \n\nProf. Nazik Hammad\n\nProfessor of Medical Oncology\, Saint Michael’s Hospital and University of Toronto Topic: Building Impactful Careers in Global Oncology: Mentorship\, Leadership and Equity in Cancer Care[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”CLICK TO REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_2lIM-Q1-Rm6JSxlo9b0jmQ”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/women-in-oncology-2/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-03-at-8.06.46-AM-e1772525890478.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260312T190000
DTEND;TZID=Africa/Nairobi:20260312T203000
DTSTAMP:20260523T014507
CREATED:20260310T140249Z
LAST-MODIFIED:20260319T174323Z
UID:41385-1773342000-1773347400@kesho-kenya.org
SUMMARY:Multiple Myeloma Care in Western Kenya
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Event Title: The Journey of Multiple Myeloma Care in Western Kenya \nAccreditation: CPD Accredited \n\nDate: 12th March 2026\nTime: 7 PM – 8:30 PM EAT\nOrganization: KESHO (Kenya Society of Haematology & Oncology)\n\nModerator:  \n\nDr. Matilda Ongondi: Consultant Physician and Clinical Haemato-Oncologist\, Kenyatta National Hospital.\n\nSpeakers \n\n\n\n\nDr. Teresa Lotodo: Senior Lecturer & Consultant Pathologist (AP/CP)Topic: Modern Diagnostic Paradigms in Multiple Myeloma: From Morphology to Molecular Risk Stratification \nDr. Rohini Radia: Consultant in BMT and HaematologyTopic: Contemporary Management of Multiple Myeloma: Sequencing\, Cellular Therapies and Risk-Adapted Strategies \nDr. Beatrice Melly: Clinical Haematologist\, Moi Teaching and Referral HospitalTopic: Building Sustainable Myeloma Care Pathways: Access\, Infrastructure and Multidisciplinary Integration \nHightlights\n\n\n\n\n\n\n\n\nThis session examined how multiple myeloma care is evolving within the Kenyan context\, bringing together perspectives on diagnostics\, treatment advances and system-level delivery. \nA central theme was the contrast between rapid global therapeutic progress and the realities of access and infrastructure in low- and middle-income settings. While survival outcomes have improved significantly with the introduction of proteasome inhibitors\, immunomodulatory agents and anti-CD38 therapies\, translating these gains into routine practice remains uneven. \nThe discussion highlighted the importance of accurate and timely diagnosis\, with a shift from morphology-based approaches towards molecular and cytogenetic risk stratification to guide treatment decisions. \nFrom a clinical perspective\, modern management is increasingly risk-adapted\, incorporating quadruplet induction regimens\, autologous stem cell transplantation and maintenance strategies. Emerging therapies\, including CAR-T cells and bispecific antibodies are redefining outcomes in relapsed disease\, though access remains limited in many settings. \nAt a systems level\, the AMPATH multiple myeloma program was presented as a model of how coordinated care can be built through partnerships\, integrating clinical care\, training and research within a learning health system. The approach emphasizes improving access\, strengthening diagnostic and treatment infrastructure\, and embedding multidisciplinary care pathways to support patients across the disease course. \nAcross the session\, a consistent message emerged: advancing myeloma care requires not only better therapies\, but systems capable of delivering them. \nKey Takeaways \n\nMyeloma outcomes are improving with novel and combination therapies.\nAccurate diagnosis and risk stratification are central to management.\nStandard care includes quadruplet induction\, ASCT and maintenance therapy.\nCAR-T and bispecific antibodies are reshaping relapsed disease care.\nSustainable progress depends on access\, infrastructure and integrated care models.
URL:https://kesho-kenya.org/event/multiple-myeloma-care-in-western-kenya/
CATEGORIES:CME 2026,Conferences,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-10-at-11.40.58-AM-1-e1773151318490.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260319T190000
DTEND;TZID=Africa/Nairobi:20260319T203000
DTSTAMP:20260523T014507
CREATED:20260318T112347Z
LAST-MODIFIED:20260319T174535Z
UID:41463-1773946800-1773952200@kesho-kenya.org
SUMMARY:Renal Cell Carcinoma: Evidence-Based Integration of Surgery and Systemic Therapy
DESCRIPTION:Evidence-Based Integration of Surgery and Systemic Therapy \nDate: 19th March 2026Time: 7 PM – 8:30 PM EAT \nMODERATORDr. Amina K. HabibMedical Oncologist\, Aga Khan University Hospital\, Nairobi \nDr. Carnjini YogeswaranConsultant Urological Surgeon | Kenyatta National HospitalTopic: Surgical Management of Locally Advanced and Oligometastatic Renal Cell Carcinoma \nDr. Douglas NyandikaPhysician and Medical Oncologist | The Nairobi HospitalTopic: Adjuvant and Metastatic Systemic Therapy in Renal Cell Carcinoma \nHighlights\nThis session examined the evolving management of renal cell carcinoma (RCC)\, focusing on how surgical and systemic approaches are increasingly integrated across the disease continuum. \nA central theme was the importance of risk-adapted\, multidisciplinary care\, particularly in settings where many patients are still present with advanced diseases. While improved imaging has increased incidental detection globally\, late-stage presentation remains common in Kenya\, shaping both prognosis and treatment strategy. \nFrom a surgical perspective\, nephron-sparing surgery remains standard for localized diseases\, while radical nephrectomy and complex resections play a critical role in locally advanced cases. In oligometastatic disease\, cytoreductive nephrectomy and metastasis-directed therapy may offer benefit in carefully selected patients\, particularly when integrated with systemic treatment strategies. \nSystemic therapy has expanded significantly\, with immune checkpoint inhibitors and targeted therapies now forming the backbone of treatment in advanced disease. Evidence from key trials demonstrates improved survival outcomes with combination regimens\, reinforcing a shift towards early and strategic use of systemic therapy\, particularly in metastatic and high-risk settings. \nIn the adjuvant setting\, therapies such as pembrolizumab have shown disease-free and overall survival benefit in selected high-risk patients\, highlighting the importance of post-surgical risk stratification and follow-up. \nHowever\, translating these advances into routine practice remains constrained by access\, cost and infrastructure. The discussion underscored the need for context-specific treatment pathways\, supported by multidisciplinary decision-making and strengthened health systems. \nAcross the session\, a consistent message emerged: optimal RCC outcomes depend on deliberate integration—of surgery\, systemic therapy and patient-centered decision-making. \nKey Takeaways \n\nRCC management requires integration of surgical and systemic therapies.\nLate-stage presentation remains a key challenge in many settings.\nNephron-sparing and radical surgery remain central to localized and advanced disease.\nImmunotherapy and targeted agents are transforming metastatic RCC outcomes.\nAdjuvant therapy is increasingly relevant in high-risk post-surgical patients.\nAccess\, cost and infrastructure continue to shape real-world implementation.\n\n 
URL:https://kesho-kenya.org/event/renal-cell-carcinoma-2/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-18-at-10.33.25-AM-e1773833004541.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260326T190000
DTEND;TZID=Africa/Nairobi:20260326T203000
DTSTAMP:20260523T014507
CREATED:20260324T112204Z
LAST-MODIFIED:20260324T112936Z
UID:41493-1774551600-1774557000@kesho-kenya.org
SUMMARY:Optimizing Care in Colorectal Cancer
DESCRIPTION:Date: 26th March 2026 \nTime: 7 PM – 8:30 PM EAT \nModerator \n\nDr. Andrew Odhiambo Medical Oncologist\, The Nairobi Hospital; Thematic Head & Program Director\, Medical Oncology\, UON\n\nSpeakers \nDr. Alex Muturi Colorectal Surgeon & Surgical Gastroenterologist\, Kenyatta University Teaching\, Research and Referral Hospital Locally Advanced Colon Cancer: Timing of Surgery Relative to Systemic Treatment \nDr. Caroline Tonio Medical Oncologist\, Clinical Research Fellow (Clinical Trials)\, The Christie NHS Foundation Trust\, UK & KUTRRH\, Kenya “Too Young for Colorectal Cancer?” Understanding the rise of EOCRC and its clinical impact. \n    	\n        CLICK TO REGISTER
URL:https://kesho-kenya.org/event/optimizing-care-in-colorectal-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-24-at-8.25.12-AM-e1774351309301.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260409T190000
DTEND;TZID=Africa/Nairobi:20260409T203000
DTSTAMP:20260523T014507
CREATED:20260407T093519Z
LAST-MODIFIED:20260407T094833Z
UID:41540-1775761200-1775766600@kesho-kenya.org
SUMMARY:Treatment in Esophageal Cancer
DESCRIPTION:THE ROLE OF MULTIMODAL Treatment in Esophageal Cancer \nDate: 9th April 2026 Time: 7 PM – 8:30 PM EAT \nMODERATOR \nDr. Omar Abdihamid Clinical Oncologist\, Garissa Regional Cancer Center | Vice President (EA)\, African Organisation for Research and Training in Cancer \nSPEAKERS \nDr. Juma Odoro Cardiothoracic and vascular surgeon\, JOOTRH Kisumu and Head of Unit Surgical Management of Esophageal Cancer \nDr. Rogers Mongare Consultant Clinical and Radiation Oncologist at Kenyatta National Hospital (KNH) The Role of Radiotherapy in the Management of Esophageal Cancer \nDr. Kevin Makori Consultant Clinical & Radiation Oncologist\, Homa Bay County Teaching and Referral Hospital | Clinical Trials Investigator\, Victoria Cancer Care & Research Center\, Nyamira Management of Metastatic Esophageal Cancer: Advances in Targeted and Combination Therapies \n    	\n        CLICK TO REGISTER
URL:https://kesho-kenya.org/event/treatment-in-esophageal-cancer/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/04/WhatsApp-Image-2026-04-07-at-12.13.58-PM-e1775554431579.jpeg
END:VEVENT
END:VCALENDAR